Skip to main
GILD
GILD logo

Gilead Sciences (GILD) Stock Forecast & Price Target

Gilead Sciences (GILD) Analyst Ratings

Based on 21 analyst ratings
Buy
Strong Buy 24%
Buy 52%
Hold 24%
Sell 0%
Strong Sell 0%

Bulls say

Gilead Sciences is poised for long-term growth primarily driven by its HIV business, with a notable PrEP-to-need ratio increase from 10 in 2021 to approximately 14, indicating a growing demand for preventative therapies. The upcoming approval of LEN for PrEP, with a PDUFA date set for June 19, 2025, is anticipated to be a critical component in enhancing the company's revenue streams. Additionally, promising data from the ASCENT-03 trial for Trodelvy could significantly expand its market by potentially doubling the eligible patient population for the therapy, further bolstering Gilead's oncology portfolio.

Bears say

The financial outlook for Gilead Sciences appears negative primarily due to the lower than anticipated uptake of lenacapavir in HIV pre-exposure prophylaxis (PrEP), leading to non risk-adjusted peak sales projected to be below $4 billion. Additionally, while proposed cuts to government funding for HIV programs are not expected to substantially impact Gilead's HIV franchise, the company is concerned about maintaining the high efficacy standards set by its leading product, Biktarvy, which may complicate future product development. Overall, these factors combined contribute to a bleak financial perspective for Gilead as it navigates both its existing portfolio and expansion into oncology.

Gilead Sciences (GILD) has been analyzed by 21 analysts, with a consensus rating of Buy. 24% of analysts recommend a Strong Buy, 52% recommend Buy, 24% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Gilead Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Gilead Sciences (GILD) Forecast

Analysts have given Gilead Sciences (GILD) a Buy based on their latest research and market trends.

According to 21 analysts, Gilead Sciences (GILD) has a Buy consensus rating as of Oct 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $117.62, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $117.62, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Gilead Sciences (GILD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.